Latest Regulatory Filings News

Optiscan Imaging Ltd has launched InSpecta™, a cutting-edge microscopic imaging device tailored for veterinary medicine, marking its strategic entry into a booming $12 billion US market. The device promises to revolutionize diagnostics and treatment for companion animals with real-time, non-invasive imaging.

Platinum Capital Limited has taken a significant step towards restructuring by lodging a draft scheme booklet to convert shareholder investments into an active ETF, aiming to resolve its persistent discount to net tangible assets.

Vinyl Group has applied to the Federal Court for an extension to lodge delayed cleansing notices, aiming to lift its ASX trading suspension. The court hearing is set for 5 June 2025, with market watchers awaiting the outcome.

High-Tech Metals Limited has successfully completed a modest capital raise through a non-renounceable entitlement offer, issuing shares at $0.15 each alongside free attaching options. The company now holds discretion over a significant shortfall placement, which could influence its capital structure in the coming months.

Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.

Neurotech International has reported positive human pharmacokinetic results for NTI164, a cannabinoid formulation designed for paediatric neurological disorders, confirming rapid absorption and a non-intoxicating profile.

EVE Health Group has initiated stability testing for its novel oral treatments targeting erectile dysfunction and dysmenorrhea, marking a crucial step toward regulatory approval in Australia. The company also finalizes its acquisition of Nextract, the developer behind these innovative formulations.

Helios Energy Limited has come under ASX compliance scrutiny after late lodgement of director interest notices, raising questions about its disclosure practices and governance.

Dimerix has activated the first clinical trial site in Japan for its pivotal Phase 3 ACTION3 study targeting FSGS, triggering a significant milestone payment from its Japanese partner FUSO Pharmaceutical.

Chorus Limited’s 2024 fibre regulatory report reveals a stable $5.9 billion asset base and revenue close to the maximum allowed, with a $153.5 million wash-up balance carried forward.

Neuren Pharmaceuticals posted record 2024 financials driven by DAYBUE royalties and advanced NNZ-2591 into Phase 3 trials, while launching a $50 million share buy-back amid volatile market sentiment.

4DMedical has submitted its CT:VQ™ software to the FDA, aiming to revolutionize lung ventilation and perfusion imaging by replacing traditional nuclear scans with a non-contrast CT-based solution.